P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children ≥ 3 Months to < 36 Months of Age
Study Location:
India
Topic:
Tuberculosis and HIV
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT00802802?term=P1070&rank=1
Enrollment:
Closed
Trial Period:
Completed
Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years of age. This study is being conducted to look at the safety of EFV, blood levels of EFV, genetic factors that may affect blood levels of EFV, and how easy it is for infants and young children to take and tolerate EFV. This information will help recommend the best doses of EFV for children younger than 3 years of age.
Ages Eligible for Study: 3 Months to 35 Months (Child)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No